For decades, most African nations have relied on imported medications to meet their healthcare needs. In this analysis, Dr. Arnaud Kaboré, a pharmacist and engineer, outlines a strategic roadmap for African policymakers to achieve pharmaceutical self-sufficiency by 2045.

Dependence as a silent health crisis

Despite progress, fewer than five African countries currently operate pharmaceutical manufacturing plants capable of exporting beyond their borders. This leaves the continent importing a staggering 94% of its medicines—an expenditure exceeding $18 billion annually. Projections suggest this figure could surge past $30 billion by 2030, according to industry forecasts. Yet the economic burden pales in comparison to the structural vulnerability it exposes.

Over 70% of public health facilities in Africa report at least one critical drug shortage per quarter. Is it acceptable that the well-being of 1.4 billion Africans hinges on industrial, logistical, and geopolitical decisions made outside the continent? The COVID-19 pandemic laid bare the consequences: recurring shortages of essential drugs like amoxicillin, insulin, and anesthetics, coupled with chronically inaccessible cancer treatments and innovative therapies. The human cost is profound—unmanaged illnesses, price surges during shortages, and paralyzed public health programs when treatments are unavailable.

Yet Africa possesses untapped potential:

• A rapidly expanding market: the African pharmaceutical sector could surpass $70 billion by 2030;
• A rich biodiversity with over 5,400 documented medicinal plants, some already integrated into official treatment protocols;
• Progressive regulatory momentum, including the African Medicines Agency (AMA), now ratified by 27 countries;
• Political will in action, with nations like Burkina Faso, Rwanda, Egypt, Morocco, Senegal, and South Africa launching ambitious local production initiatives.

Redefining African healthcare: a sustainable pharmaceutical industry

A critical misstep has been attempting to replicate the models of global pharmaceutical giants without first establishing foundational capacities or local value chains. Industrialization cannot be achieved through imported equipment alone—it demands simultaneous investment in human capital, technical expertise, and indigenous industrial assets. Without this, local production often becomes costlier than imports, perpetuating dependence on raw materials, technology, and foreign expertise. True pharmaceutical self-sufficiency in Africa will require rigor, methodical planning, and a long-term vision.

To build a resilient pharmaceutical sector, Africa must anchor its strategy in endogenous strengths: a growing market, medicinal biodiversity, regulatory progress, and unwavering political commitment. This analysis offers a pragmatic roadmap for public leaders to reclaim the continent’s health sovereignty by 2045—producing locally to heal locally, and ultimately, contributing to global health security. The path forward is clear: Africa must industrialize its pharmaceutical sector within a broader vision of continental development, backed by clear policies, adequate resources, and unshakable determination.

Dr. Arnaud Kaboré

Pharmacist and Health Sector Executive